AVID BIOSERVICES INC. - COMMON STOCK

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments

29 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021

22 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)

25 May 2021 08:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock

15 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

17 Mar 2021 08:05:00 By Nasdaq GlobeNewswire

Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes

10 Mar 2021 00:20:03 By Nasdaq GlobeNewswire

Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes

08 Mar 2021 17:01:00 By Nasdaq GlobeNewswire

Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

03 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021

01 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan

22 Feb 2021 08:05:00 By Nasdaq GlobeNewswire

Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

03 Feb 2021 07:00:00 By Nasdaq GlobeNewswire